Skip to main content

Advertisement

Table 1 Characteristics of included trials on XST for ACI

From: Xuesaitong injection as one adjuvant treatment of acute cerebral infarction: a systematic review and meta-analysis

Study ID Sex (M/F) Age (a) Course of disease (h) N (E/C) Intervention Duration (days) Outcomes ADR/ADE
Experimental Control
Li 1999 [15] 29/33 62.9 ± 7.1 (57 ~ 71) ≤48 31/31 XST 400 mg + WM WM (Defibrase et al.) 14 Total effective rate, changes in cerebral blood flow and hemorheology Unclear
Zhang 2002 [16] 52/48 53.0 (37 ~ 70) ≤72 60/40 Luotai 400 mg + WM Xiaoshuanling + WM 14 Total effective rate Unclear
Yuan 2003 [17] 37/25 42 ~ 79 ≤72 32/30 XST 20 ml + WM WM (Piracetam et al.) 15 Total effective rate, changes in hemorheology Unclear
Li 2003 [18] 69/27 55.8 (42 ~ 71) ≤72 48/48 XST 400 mg WM (Dextran 40 + citicoline) 15 Total effective rate Unclear
Li 2005 [19] - 48 ~ 73 ≤72 80/76 XST 200 mg + WM WM 20 Total effective rate E 3
He 2006 [20] 48/32 59.3 ± 12.1 (46 ~ 80) ≤72 40/40 XST 10 ml + WM Dextran 40 + WM 14 Total effective rate, neurological deficit score None
Wang 2006 [21] 34/21 63.8 (39 ~ 79) ≤24 36/19 XST 600 mg + WM Venoruton + WM 21 Total effective rate None
Yuan 2006 [22] 64/31 63.0 ± 10.4 (46 ~ 74) ≤24 49/46 XST 250 ~ 500 mg + WM WM (Defibrase et al.) 15 Total effective rate E 3
C 7
Zhao 2006 [23] 43/38 60.9 ± 8.1 (45 ~ 70) ≤72 40/41 XST 10 ml + WM WM (Sodium ozagrel + Defibrase et al.) 14 Total effective rate, changes in hemorheology Unclear
Li 2007 [24] 54/36 59.5 ± 13.2 (48 ~ 79) ≤48 45/45 XST 10 ml + WM Dextran 40 + WM 15 Total effective rate None
Wang 2007A [25] 50/26 63.6 (39 ~ 82) ≤24 50/26 XST 600 mg + WM Venoruton + WM 21 Total effective rate None
Wang 2007B [26] - 69.4 (43 ~ 80) ≤72 30/30 XST 20 ml + WM WM (Venoruton et al.) 14 Total effective rate None
Rong 2008 [27] 50/46 59.1 ± 8.4 (39 ~ 77) ≤72 51/45 XST 400 mg + WM Venoruton + WM 14 Total effective rate, neurological deficit score, Modified Barthel Index, changes in hemorheology None
Zhang 2008 [28] 70/50 56 ± 11 (48 ~ 78) ≤48 65/65 XST 200 ~ 400 mg + WM WM 15 Total effective rate, changes in hemorheology Unclear
Zi 2008 [29] 49/33 59.5 ± 13.2 (48 ~ 79) ≤48 41/41 XST 10 ml + WM Dextran 40 + WM 15 Total effective rate, neurological deficit score None
Duan 2009 [30] 35/34 64.5 ± 8.2 (33 ~ 75) ≤48 36/33 XST 500 mg + WM WM 14 Total effective rate None
Ma 2009 [31] 117/83 65.1 ± 7.0 (45 ~ 85) ≤72 100/100 XST 400 mg + WM Venoruton + WM 15 Total effective rate, neurological deficit score, changes in hemorheology, glycemia and lipidemia E 9
C 10
Cai 2011 [32] 42/18 64.2 (47 ~ 86) ≤48 30/30 XST 400 mg + WM WM (Buflomedil hydrochloride + Low molecular heparin) 14 Total effective rate, neurological deficit score E 2
C 1
Fu 2011 [33] 62/58 55.4 ± 5.1 ≤48 64/58 XST 400 mg + WM WM (Sodium ozagrel et al.) 14 Total effective rate, neurological deficit score None
He 2011 [34] 57/65 59 ~ 78 ≤72 62/60 XST 200 mg + WM WM (Citicoline, Aspirin) 14 Total effective rate, neurological deficit score None
Wang 2011 [35] 45/37 55.87 ± 5.23 (42 ~ 76) ≤19 41/41 XST 400 mg + WM WM 21 Total effective rate, Hs-CRP Unclear
Yang 2012 [36] 33/27 57 ± 4 (47 ~ 68) ≤48 30/30 XST 400 mg + WM WM (Sodium ozagrel et al.) 14 Total effective rate C 2
Song 2013 [37] 117/43 62.1 ≤24 80/80 XST 400 mg + WM WM 15 Total effective rate Unclear
  1. NOTE: M: Males; F: Females; E: Experimental group; C: Control group; ADR: Adverse drug reactions; ADE: Adverse drug events; XST: Xuesaitong Injection; WM: Conventional therapy with western medicines, such as Dextran-40, Mannitol, Aspirin, Citicoline, Venoruton, Defibrase, Sodium ozagrel, et al.